J. Janes

发表

Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities.

T. S. Chee, D. S. Kim, S. H. Lee, 2021, European journal of preventive cardiology.

Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment

Weiqun Li, Melissa G. Works, P. Murray, 2017, Journal of Immunotherapy for Cancer.

Cytokine regulation of MMP-9 in peripheral glia: Implications for pathological processes and pain in injured nerve

R. Myers, V. Shubayev, S. Chattopadhyay, 2007, Brain, Behavior, and Immunity.

A shed form of LDL receptor-related protein-1 regulates peripheral nerve injury and neuropathic pain in rodents.

R. Myers, A. Gaultier, S. L. Gonias, 2008, The Journal of clinical investigation.

Omega-3 polyunsaturated fatty acid impairment of early host resistance against Listeria monocytogenes infection is independent of neutrophil infiltration and function.

Charles R. Brown, K. Fritsche, R. Irons, 2005, Cellular immunology.

Comparison of AMG 416 and cinacalcet in rodent models of uremia

D. Maclean, D. Mendel, Randolph M. Johnson, 2014, BMC Nephrology.

Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer

Jennifer B Dennison, S. Demo, M. Bennett, 2014, Molecular Cancer Therapeutics.

Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer.

Saman Sadeghi, David B Shackelford, Johannes Czernin, 2017, Cell reports.

The Low-Density Lipoprotein Receptor-Related Protein Is a Pro-Survival Receptor in Schwann Cells: Possible Implications in Peripheral Nerve Injury

A. Gaultier, W. Campana, J. Janes, 2006, The Journal of Neuroscience.

Abstract 1416: CB-839, a novel potent and selective glutaminase inhibitor, has broad antiproliferative activity in cell lines derived from both solid tumors and hematological malignancies

S. Demo, Dong Zhang, M. Bennett, 2014 .

Abstract 1877: Anti-tumor activity of novel, potent, selective and orally-bioavailable glutaminase inhibitors.

S. Demo, A. Richardson, M. Bennett, 2013 .

Pharmacology of AMG 416 (Velcalcetide), a Novel Peptide Agonist of the Calcium-Sensing Receptor, for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients

J. Tomlinson, D. Maclean, D. Mendel, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Small Molecule Therapeutics Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer

S. Demo, M. Bennett, F. Parlati, 2014 .

Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities.

T. S. Chee, D. S. Kim, S. H. Lee, 2022, European journal of preventive cardiology.

Metabolomic, Proteomic and Genomic Profiling Identifies Biomarakers of Sensitivity to Glutaminase Inhibitor CB-839 in Multiple Myeloma

M. Bennett, F. Parlati, A. Mackinnon, 2015 .